MCID: ACT134
MIFTS: 51

Acute Liver Failure

Categories: Blood diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Liver diseases, Metabolic diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Acute Liver Failure

MalaCards integrated aliases for Acute Liver Failure:

Name: Acute Liver Failure 58 54 37
Fulminant Hepatic Failure 58 36 29 6
Acute Hepatic Failure 58 6
Hepatic Failure Fulminant 54
Liver Failure, Acute 71
Liver Failure Acute 54

Characteristics:

Orphanet epidemiological data:

58
acute liver failure
Prevalence: 1-5/10000 (Europe);

Classifications:

Orphanet: 58  
Rare hepatic diseases


External Ids:

KEGG 36 H01712
MESH via Orphanet 44 D017114
ICD10 via Orphanet 33 K72.0
UMLS via Orphanet 72 C0162557
Orphanet 58 ORPHA90062
UMLS 71 C0162557

Summaries for Acute Liver Failure

KEGG : 36 Fulminant hepatic failure (FHF) is a life-threatening condition characterized by the rapid deterioration of liver functions and hepatic encephalopathy. FHF is with the basic definition of the onset of hepatic encephalopathy within 8 weeks of the appearance of the first symptoms like jaundice, fever, nausea, and vomiting. The prothrombin time is prolonged by 4-6 seconds or more. While the etiologies of FHF are multiple and varied, viral hepatitis is the most frequent cause. Around 40-60% of patients with FHF are thought to be due to some viral infection. The prognosis is dependent on several factors, including the underlying cause of liver failure. For instance, it is well known that the spontaneous recovery rates from FHF from such etiologies as hepatitis A and acetaminophen toxicity are high, whereas those same rates for other types of viral hepatitis and idiosyncratic drug reactions are quite low. Identification of the cause of FHF is important because some causes have specific treatment interventions or antidotes. Specific therapies include N-acetylcysteine for acetaminophen overdose, and acyclovir for herpesvirus infection. Different therapeutic options such as complete exchange blood transfusion, corticosteroids, and plasma pheresis, have been tried. However, the overall prognosis for patients with FHF is quite poor, with survival rates usually reported between 10% and 30% without liver transplantation.

MalaCards based summary : Acute Liver Failure, also known as fulminant hepatic failure, is related to hepatitis a and infantile liver failure syndrome 1. An important gene associated with Acute Liver Failure is RINT1 (RAD50 Interactor 1). The drugs Lamivudine and Entecavir have been mentioned in the context of this disorder. Affiliated tissues include Liver, brain and bone, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 74 Acute liver failure is the appearance of severe complications rapidly after the first signs (such as... more...

Related Diseases for Acute Liver Failure

Diseases in the Liver Disease family:

Liver Failure, Infantile, Transient Infantile Liver Failure Syndrome 1
Infantile Liver Failure Syndrome 2 Infantile Liver Failure Syndrome 3
Acute Liver Failure

Diseases related to Acute Liver Failure via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 637)
# Related Disease Score Top Affiliating Genes
1 hepatitis a 32.3 GPT F2 ALB
2 infantile liver failure syndrome 1 32.0 SLC17A5 GPT F2 ALB
3 paracetamol poisoning 31.0 GC F2
4 hepatitis e 30.8 GPT F2 ALB
5 hepatic coma 30.7 TSPO GPT F2 ALB
6 wilson disease 30.6 GPT F2 ALB
7 autoimmune hepatitis 30.5 SLC17A5 GPT F2 ALB
8 drug-induced hepatitis 30.5 GPT ALB
9 hepatorenal syndrome 30.4 GPT F2 ALB
10 lactic acidosis 30.4 POLG GPT F2
11 exanthem 30.3 GPT F2 ALB
12 fatty liver disease 30.3 SLC17A5 GPT ALB
13 splenic infarction 30.3 GPT F2
14 dengue hemorrhagic fever 30.2 GPT F2 ALB
15 portal hypertension 30.2 GPT F2 ALB
16 fatty liver disease, nonalcoholic 1 30.2 SLC17A5 GPT
17 metabolic acidosis 30.2 GPT F2 ALB
18 hellp syndrome 30.2 SLC17A5 GPT F2
19 cholestasis 30.1 SLC17A5 GPT F2 ALB
20 liver disease 30.1 SLC17A5 HGF GPT F2 ALB
21 hepatitis d 30.1 GPT F2
22 acute kidney failure 30.0 HGF GPT F2 ALB
23 non-alcoholic steatohepatitis 30.0 SLC17A5 GPT
24 inherited metabolic disorder 30.0 GPT F2 ALB
25 tricuspid valve insufficiency 30.0 F2 ALB
26 bilirubin metabolic disorder 30.0 SLC17A5 GPT F2 ALB
27 scrub typhus 30.0 SLC17A5 GPT
28 non-a-e hepatitis 29.9 F2 ALB
29 hepatic infarction 29.9 GPT F2 ALB
30 cholecystitis 29.9 GPT F2 ALB
31 drug allergy 29.9 GPT F2 ALB
32 bronchopneumonia 29.9 GPT ALB
33 alcohol use disorder 29.9 SLC17A5 GPT ALB
34 acute kidney tubular necrosis 29.9 HGF ALB
35 sclerosing cholangitis 29.9 GPT F2 ALB
36 abdominal tuberculosis 29.8 F2 ALB
37 granulomatous hepatitis 29.8 GPT ALB
38 hepatic encephalopathy 29.8 TSPO SLC17A5 GPT GC F2 ALB
39 cardiac tamponade 29.8 F2 ALB
40 babesiosis 29.8 GPT ALB
41 papilledema 29.8 F2 ALB
42 viral hepatitis 29.8 SLC17A5 GPT FGL2 F2 ALB
43 anuria 29.8 F2 ALB
44 acute cystitis 29.7 GPT F2 ALB
45 liver cirrhosis 29.7 SLC17A5 HGF GPT F2 ALB
46 ascending cholangitis 29.7 GPT F2 ALB
47 intestinal volvulus 29.7 GPT F2 ALB
48 pericardial effusion 29.7 GPT F2 ALB
49 cholangitis 29.7 SLC17A5 GPT F2 ALB
50 primary biliary cirrhosis 29.6 SLC17A5 GPT F2 ALB

Graphical network of the top 20 diseases related to Acute Liver Failure:



Diseases related to Acute Liver Failure

Symptoms & Phenotypes for Acute Liver Failure

MGI Mouse Phenotypes related to Acute Liver Failure:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.76 ALB F2 FGL2 GC HGF NBAS
2 homeostasis/metabolism MP:0005376 9.61 ALB F2 FGL2 GC NBAS POLG
3 mortality/aging MP:0010768 9.28 ALB F2 FGL2 HGF NBAS POLG

Drugs & Therapeutics for Acute Liver Failure

Drugs for Acute Liver Failure (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 203)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
2
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
3
rituximab Approved Phase 4 174722-31-7 10201696
4
Rifaximin Approved, Investigational Phase 4 80621-81-4 6436173 46783403
5
Lactulose Approved Phase 4 4618-18-2 11333
6
Ornithine Approved, Nutraceutical Phase 4 3184-13-2, 70-26-8 6262
7
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
8 Neurotransmitter Agents Phase 4
9 N-Methylaspartate Phase 4
10 Excitatory Amino Acids Phase 4
11 Excitatory Amino Acid Agonists Phase 4
12 Reverse Transcriptase Inhibitors Phase 4
13 Anti-Retroviral Agents Phase 4
14 Anti-HIV Agents Phase 4
15 Gastrointestinal Agents Phase 4
16 Immunologic Factors Phase 4
17 Vaccines Phase 4
18 Cathartics Phase 4
19 Polyethylene glycol 3350 Phase 4
20 Laxatives Phase 4
21 Pharmaceutical Solutions Phase 4
22
Pioglitazone Approved, Investigational Phase 3 111025-46-8 4829
23
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
24
Lenograstim Approved, Investigational Phase 3 135968-09-1
25
Tacrolimus Approved, Investigational Phase 3 104987-11-3 445643 439492 6473866
26
Everolimus Approved Phase 3 159351-69-6 6442177 70789204
27
Sirolimus Approved, Investigational Phase 3 53123-88-9 5284616 6436030 46835353
28
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
29
Terlipressin Approved, Investigational Phase 3 14636-12-5 72081
30
Formaldehyde Approved, Vet_approved Phase 2, Phase 3 50-00-0 712
31 Hypoglycemic Agents Phase 3
32 Adjuvants, Immunologic Phase 3
33 Epoetin alfa Phase 3 113427-24-0
34 Immunosuppressive Agents Phase 3
35 Antifungal Agents Phase 3
36 Cyclosporins Phase 3
37 Natriuretic Agents Phase 3
38 diuretics Phase 3
39 Antibiotics, Antitubercular Phase 3
40 Antitubercular Agents Phase 3
41 Vasoconstrictor Agents Phase 3
42 Trace Elements Phase 3
43 Micronutrients Phase 3
44 Nutrients Phase 3
45 Vitamins Phase 3
46 Antihypertensive Agents Phase 3
47 Complement C3a Phase 3
48
Mycophenolic acid Approved Phase 1, Phase 2 24280-93-1 446541
49
Phenylacetic acid Approved Phase 2 103-82-2 999
50
Pentoxifylline Approved, Investigational Phase 1, Phase 2 6493-05-6 4740

Interventional clinical trials:

(show top 50) (show all 148)
# Name Status NCT ID Phase Drugs
1 Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography Unknown status NCT02757170 Phase 4
2 Safety and Efficacy of Steroids in the Management of Fulminant Hepatic Failure Due to Hepatitis A Virus in the Pediatric Age Group Completed NCT02375867 Phase 4 prednisolone;methylprednisolone
3 Influence of Methylprednisolone Pulse Therapy on Liver Function in Patients With Graves' Orbitopathy Completed NCT03667157 Phase 4 every week IVMP therapy;very high doses IVMP therapy
4 Tenofovir Reduces Morbidity and Mortality in Patients With Spontaneous Reactivation of Hepatitis B Presenting as Acute-on-chronic Liver Failure (ACLF): A Randomized Placebo Controlled Trial Completed NCT01074645 Phase 4 Tenofovir disoproxil fumarate (TDF)
5 A Randomized Controlled Trial of Lamivudine in Acute Hepatitis B Completed NCT00380614 Phase 4 Lamivudine
6 Prophylactic Use of Entecavir for Chemotherapy Associated With Hepatitis B Reactivation in HBsAg (-), Anti-HBc (+) Non-Hodgkin's Lymphoma Patients: a Randomized Controlled Trial Completed NCT00926757 Phase 4 Entecavir prophylaxis;Therapeutic entecavir
7 Effect of Early Nutritional Therapy on Frailty, Functional Outcomes and Recovery of Undernourished Medical Inpatients Trial: The EFFORT Trial Completed NCT02517476 Phase 4
8 Efficacy of Intravenous 'L-ornithine L-aspartate' in Reversal of Overt Acute Hepatic Encephalopathy in Patients With Liver Cirrhosis: a Prospective, Randomized, Double-blind, Placebo Controlled Trial Completed NCT01722578 Phase 4 L-ornithine L-aspartate;Placebo
9 Pharmacokinetics and Safety of Treatment With Paracetamol in Children and Adults With Spinal Muscular Atrophy and Cerebral Palsy Recruiting NCT03648658 Phase 4 Paracetamol 120Mg/5mL Oral Suspension
10 Effectiveness of Booster Vaccination With 1 or 2 Doses of Hepatitis A Vaccine Among HIV-infected Patients During an Ongoing Outbreak in Taiwan Recruiting NCT03855176 Phase 4 Vaqta Injectable Product
11 Therapeutic Efficacy of Oral PEG3350 Plus Lactulose Versus Lactulose Alone in Patients of Acute on Chronic Liver Failure With Overt Hepatic Encephalopathy: A Single Blind Prospective Randomized Controlled Study Recruiting NCT03987893 Phase 4 PEG-3350 with Electolytes;Lactulose
12 A Multi-Center Trial to Study Acute Liver Failure: N-Acetylcysteine (NAC) Open Label Use Study Terminated NCT00896025 Phase 4 N-acetylcysteine
13 Minocycline Administration During Human Liver Transplantation Withdrawn NCT02712775 Phase 4 Minocycline (yes/no);Placebo
14 Prevention of Coronary Artery in STENT Restenosis With the Combined Use of Pioglitazone and Sirolimus-Eluting Coronary Stent Unknown status NCT00376870 Phase 3 Pioglitazone;Placebo
15 Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen Completed NCT00004467 Phase 3 N-acetylcysteine (NAC);Placebo
16 A Multi-center Study of the Safety and Efficacy of N-acetylcysteine in the Treatment of Acute Liver Failure in Pediatric Patients Not Caused by Acetaminophen. Completed NCT00248625 Phase 3 N-acetylcysteine;Placebo
17 Randomized Placebo-controlled Trial to Assess the Efficacy of Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO) in the Survival of Patients With Acute-on-chronic Liver Failure (ACLF) Completed NCT01383460 Phase 3 Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO);Placebo
18 Efficacy and Safety of the Albumin Dialysis MARS® Therapy in Patients With Fulminant and Subfulminant Hepatic Failure Completed NCT00224705 Phase 3
19 A Prospective Randomised, Open-labeled, Trial Comparing Sirolimus-Containing Versus mTOR-Inhibitor-Free Immunosuppression in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma Completed NCT00355862 Phase 3 CNI, MMF, Steroids, Aza etc. (mTOR inhibitor free);Sirolimus
20 Comparison of Bovine Colostrum Versus Placebo in Treatment of Severe Alcoholic Hepatitis: A Randomized Double Blind Controlled Trial Recruiting NCT02473341 Phase 3 Bovine Colostrum;Placebo
21 13C-Methacetin Breath Test for the Prediction of Outcome in in Acute Liver Injury or Acute Liver Failure Active, not recruiting NCT02786836 Phase 2, Phase 3 13C-Methacetin
22 A Randomized, Open-Label, Multicenter, Controlled Study to Assess Safety and Efficacy of ELAD® in Subjects With Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure Terminated NCT01829347 Phase 3
23 Registry Protocol for Tracking the Incidence of Transplant, the Incidence and Type of Cancer, and Survival Rate of Subjects Participating in Protocol VTI-206 (NCT00973817) Withdrawn NCT01452295 Phase 2, Phase 3 ELAD (Extracorporeal Liver Assist System)
24 A Pivotal, Within Subject, Comparison of the LFT™ Dye Monitor System to the Indocyanine Green Dye (ICG) Serial Blood Plasma Disappearance Rate in Patients With Impaired and Non-Impaired Hepatic Function Withdrawn NCT02552901 Phase 3 0.1 mg/kg ICG Dose;0.5 mg/kg ICG dose
25 Phase I/II Study of Recombinant Human Hepatocyte Growth Factor in Fulminant and Late-Onset Hepatic Failure Unknown status NCT00225901 Phase 1, Phase 2 Recombinant human hepatocyte growth factor
26 A Multicentre, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and the Safety of ALF-5755 in Patients With Nonacetaminophen Severe Acute Hepatitis and Early Stage Acute Liver Failure Unknown status NCT01318525 Phase 2 ALF-5755;Saline solution (0.9% NaCl)
27 Therapeutic Efficacy of L-Ornithine L-Aspartate Infusion in Patients With Acute Liver Failure: A Double- Blind, Randomized, Placebo- Controlled Study Unknown status NCT00470314 Phase 2 L-Ornithine L-Aspartate
28 Molecular Adsorbent Recirculating System (MARS®) for the Treatment of Patients With Hypoxic Hepatitis - a Prospective Randomized Controlled Clinical Study Unknown status NCT01690845 Phase 2
29 Infusion of Third-party Mesenchymal Stem Cells After Renal or Liver Transplantation. A Phase I-II, Open-label, Clinical Study Unknown status NCT01429038 Phase 1, Phase 2
30 A Randomized Controlled Clinical Trial on the Efficacy and Safety of Glucocorticosteroid in the Patients With Chronic Recurrent Drug-induced Liver Injury Unknown status NCT02651350 Phase 1, Phase 2 Methylprednisolone;Standard Treatment
31 Phase 2 Evaluation of the Vitagen Extracorporeal Liver Assist Device (ELAD) System in the Management of the Patients With Fulminant Hepatic Failure Completed NCT00030225 Phase 2
32 Emergency Use of OCR-002 (Ornithine Phenylacetate) in the Treatment of Patients With Acute Liver Failure Completed NCT01634230 Phase 2 OCR-002
33 A Phase 2a Study to Evaluate the Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in the Treatment of Patients With Acute Liver Failure/Severe Acute Liver Injury Completed NCT01548690 Phase 2 Ornithine Phenylacetate
34 Prospective Pilot Study Assessing Safety and Efficacy of Single Pass Albumin Dialysis in Patients With Acute on Chronic Liver Failure Completed NCT00764049 Phase 1, Phase 2
35 Infusione Sistemica e Loco-regionale di N-Acetilcisteina Nel Prelievo di Fegato: Uno Studio Prospettico Randomizzato Controllato. Fase II. Completed NCT01394497 Phase 2 N-acetylcystein
36 Safety & Efficacy of the Extracorporeal Liver Assist Device (ELAD) in Patients With Acute on Chronic Hepatitis (AOCH) Completed NCT00771446 Phase 1, Phase 2
37 Efficacy of Combination Therapy of Glucocorticoids, and Bovine Colostrum in Treatment of Severe Alcoholic Hepatitis: A Pilot Study. Completed NCT02265328 Phase 2
38 A Phase 2b Study to Evaluate Safety and Efficacy of LifeLiver (Bio Artificial Liver) in Acute or Acute-on-Chronic Liver Failure Patients Waiting Emergent Liver Transplantation Recruiting NCT03882346 Phase 2
39 Multicenter Phase II Safety and Preliminary Efficacy Study of 2 Dose Regimens of HepaStem in Patients With Acute on Chronic Liver Failure Recruiting NCT02946554 Phase 2
40 An Interventional, Single Arm, Multicenter, Phase I/IIa Clinical Trial to Investigate the Efficacy and Safety of Allo-APZ2-ACLF for the Treatment of Acute-on-Chronic Liver Failure (ACLF) Recruiting NCT03860155 Phase 1, Phase 2
41 Safety and Efficacy of Human Unbilical Cord Derived-mesenchymal Stem Cells Treatment for Patients With Decompensated Liver Cirrhosis Recruiting NCT03945487 Phase 2
42 The Efficacy and Safety of 36 Weeks Short-Term Optimization Treatment of Glucocorticosteroid in the Patients With Chronic Recurrent Drug-Induced Liver Injury Recruiting NCT03266146 Phase 1, Phase 2 36 Weeks Methylprednisolone;48 weeks Methylprednisolone
43 Mesenchymal Stem Cell Transplantation for Acute-on-Chronic Liver Failure Not yet recruiting NCT03863002 Phase 1, Phase 2
44 Functional Consequences and Therapeutic Intervention in Hampered Production of Cysteine, Glutathione and Taurine in Classical Homocystinuria Not yet recruiting NCT04015557 Phase 1, Phase 2 Acetaminophen;N-acetylcysteine
45 An Open-Label, Multicenter, Historically-Controlled Study to Assess Safety and Efficacy of ELAD in Subjects With Acute Liver Failure (ALF) Terminated NCT01875874 Phase 2
46 A Placebo-Controlled, Multicenter, Double-Blind, Randomized, Pharmacokinetic and Pharmacodynamic Trial of IDN-6556 in Subjects With Acute-on-Chronic Liver Failure Terminated NCT01937130 Phase 2 IDN-6556
47 Safety and Efficacy of the Extracorporeal Liver Assist Device (ELAD®) In Patients With Fulminant Hepatic Failure (FHF) Withdrawn NCT00832728 Phase 2
48 The Use of Human Hepatocyte Transplantation as a Life Support Bridge in Terminal Liver Failure. Withdrawn NCT00805610 Phase 1, Phase 2
49 Macrophage Activation, Assessed by Macrophage Markers Soluble CD163 and Soluble CD206, as Indication of Early Liver Cell Damage in Paracetamol Overdose Completed NCT03679442 Phase 1 N-acetylcysteine
50 A Randomized, Open-label, Single Dose, Crossover Design Phase I Study to Evaluate the Pharmacokinetics of Acetaminophen and Its Toxic Metabolites With 2 Formulations (Panadol and SafeTynadol) in Healthy Volunteers Completed NCT03451487 Phase 1 Panadol®;SafeTynadol®

Search NIH Clinical Center for Acute Liver Failure

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Acute Liver Failure cell therapies at LifeMap Discovery.

Genetic Tests for Acute Liver Failure

Genetic tests related to Acute Liver Failure:

# Genetic test Affiliating Genes
1 Fulminant Hepatic Failure 29

Anatomical Context for Acute Liver Failure

MalaCards organs/tissues related to Acute Liver Failure:

40
Liver, Brain, Bone, Testes, Bone Marrow, Kidney, T Cells
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Acute Liver Failure:
# Tissue Anatomical CompartmentCell Relevance
1 Liver Liver Lobule Hepatocytes Affected by disease, potential therapeutic candidate

Publications for Acute Liver Failure

Articles related to Acute Liver Failure:

(show top 50) (show all 8886)
# Title Authors PMID Year
1
Vasoactive mediators in patients with acute liver failure treated with albumin dialysis. 61 54
19780957 2010
2
Genotype-confirmed alanine aminotransferase deficiency in a Chinese patient with acute liver failure: a potential diagnostic pitfall. 61 54
20025492 2010
3
Is it possible to gain extra waiting time to liver transplantation in acute liver failure patients using albumin dialysis? 61 54
19788458 2009
4
Predictive criteria for the outcome of patients with acute liver failure treated with the albumin dialysis molecular adsorbent recirculating system. 54 61
19788457 2009
5
[Establishment of pig acute liver failure model and the role of pig fibrinogen-like protein 2]. 54 61
19785959 2009
6
Translational research to identify clinical applications of hepatocyte growth factor. 61 54
19624764 2009
7
De novo mutations in POLG presenting with acute liver failure or encephalopathy. 61 54
19252446 2009
8
Acute liver failure: managing coagulopathy and the bleeding diathesis. 61 54
19460532 2009
9
A case-control study of single-pass albumin dialysis for acetaminophen-induced acute liver failure. 61 54
19590182 2009
10
[The significance of Gc-globulin in clinical practice]. 54 61
19002085 2008
11
Rapid diagnosis of Wilson disease in acute liver failure: no more waiting for the ceruloplasmin level? 54 61
18821595 2008
12
Acute hepatitis C. 54 61
18657711 2008
13
Predictive value of serum-soluble CD154 in fulminant hepatic failure. 61 54
18652769 2008
14
Homozygous W748S mutation in the POLG1 gene in patients with juvenile-onset Alpers syndrome and status epilepticus. 54 61
18294203 2008
15
Acetaminophen-induced acute liver failure treated with single-pass albumin dialysis: report of a case. 54 61
18609519 2008
16
Alpers syndrome with prominent white matter changes. 54 61
17923349 2008
17
Cytokine profiles in acute liver failure treated with albumin dialysis. 61 54
18181803 2008
18
Serum apoptosis markers in acute liver failure: a pilot study. 61 54
17967565 2007
19
Albumin dialysis: an update. 61 54
18089976 2007
20
[Establishment of a D-galactosamine/lipopolysaccharide induced acute-on-chronic liver failure model in rats]. 61 54
17963606 2007
21
Actin-free Gc globulin: a rapidly assessed biomarker of organ dysfunction in acute liver failure and cirrhosis. 54 61
17763400 2007
22
Fulminant liver failure from acute autochthonous hepatitis E in France: description of seven patients with acute hepatitis E and encephalopathy. 61 54
17439518 2007
23
Protein chemical characterization of Gc globulin (vitamin D-binding protein) isoforms; Gc-1f, Gc-1s and Gc-2. 54 61
17360250 2007
24
Serum hepatocyte growth factor and vascular endothelial growth factor in children with acute liver failure. 61 54
17255836 2007
25
Comparison of rocket and crossed immuno-electrophoresis assays for determination of the level of actin complexing of Gc globulin. 61 54
17852808 2007
26
Acute liver failure due to leptospirosis successfully treated with MARS (molecular adsorbent recirculating system) dialysis. 61 54
17203354 2007
27
Drug-induced liver injury. 54 61
17408305 2007
28
The acidifying effect of lactate is neutralized by the alkalinizing effect of hypoalbuminemia in non-paracetamol-induced acute liver failure. 54 61
16750869 2006
29
Ornithine transcarbamoylase deficiency presenting with acute liver failure. 54 61
16802108 2006
30
Induction of murine liver damage by overexpression of CD40 ligand provides an experimental model to study fulminant hepatic failure. 54 61
16871541 2006
31
Bridging to transplantation in acute liver failure in a 7-month-old infant. 61 54
16810489 2006
32
Large-scale purification and characterization of non-glycosylated Gc globulin (vitamin D-binding protein) from plasma fraction IV. 61 54
16402919 2006
33
Ratio of circulating follistatin and activin A reflects the severity of acute liver injury and prognosis in patients with acute liver failure. 61 54
16509861 2006
34
Development of a rapid semi-quantitative immunochromatographic assay for serum hepatocyte growth factor and its usefulness in acute liver failure. 54 61
16293443 2005
35
Mucosal repair and growth factors: recombinant human hepatocyte growth factor as an innovative therapy for inflammatory bowel disease. 61 54
16261428 2005
36
The decrease in cytokine concentration during albumin dialysis correlates with the prognosis of patients with acute on chronic liver failure. 54 61
16182740 2005
37
Etiology, outcome and prognostic indicators of childhood fulminant hepatic failure in the United kingdom. 61 54
15861019 2005
38
Mild hypothermia prevents brain edema and attenuates up-regulation of the astrocytic benzodiazepine receptor in experimental acute liver failure. 54 61
15826719 2005
39
Transplantation of human hepatocytes cultured with deleted variant of hepatocyte growth factor prolongs the survival of mice with acute liver failure. 61 54
15912107 2005
40
The effect of albumin dialysis on cytokine levels in acute liver failure and need for liver transplantation. 61 54
15848631 2005
41
Intraoperative blood transfusion requirement is the main determinant of early surgical re-intervention after orthotopic liver transplantation. 54 61
15717214 2005
42
Anti-inflammatory effects of hepatocyte growth factor: induction of interleukin-1 receptor antagonist. 61 54
15627638 2004
43
[Intensive care medicine 2004]. 61 54
15490076 2004
44
Evaluation of serum albumin utilization in inpatient at a private hospital in Bangkok. 54 61
15340186 2004
45
[Use of albumin dialysis with the MARS device to treat a case acute liver failure after partial hepatic resection]. 61 54
15274801 2004
46
[Albumin dialysis MARS (Molecular Adsorbent Recirculating System) as a bridge for liver transplantation in acute liver failure. Report of three cases]. 61 54
15279147 2004
47
Albumin dialysis: a new therapeutic strategy for intoxication from protein-bound drugs. 54 61
14735236 2004
48
Hepatocyte growth factor/scatter factor in development, inflammation and carcinogenesis: its expression and role in oral tissues. 61 54
14596869 2003
49
Up-regulation of hepatocyte growth factor caused by an over-expression of transforming growth factor beta, in the rat model of fulminant hepatic failure. 54 61
14697288 2003
50
Changes in serum levels of hepatocyte growth factor in patients undergoing adult-to-adult living-donor liver transplantation. 54 61
14688531 2003

Variations for Acute Liver Failure

ClinVar genetic disease variations for Acute Liver Failure:

6 ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 RINT1 NM_021930.6(RINT1):c.1109T>C (p.Leu370Pro)SNV Pathogenic 599396 rs1562849964 7:105190709-105190709 7:105550262-105550262
2 POLG2 NM_007215.3(POLG2):c.544C>T (p.Arg182Trp)SNV Likely pathogenic 252958 rs886037843 17:62492543-62492543 17:64496425-64496425
3 MT-CO3 NC_012920.1:m.9355A>TSNV Uncertain significance 523307 rs1556423663 MT:9355-9355 MT:9355-9355
4 RINT1 NM_021930.6(RINT1):c.1333+1G>ASNV Uncertain significance 547947 rs375350359 7:105190934-105190934 7:105550487-105550487

Expression for Acute Liver Failure

Search GEO for disease gene expression data for Acute Liver Failure.

Pathways for Acute Liver Failure

GO Terms for Acute Liver Failure

Cellular components related to Acute Liver Failure according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.63 TSPO GPT GC FGL2 F2 ALB
2 blood microparticle GO:0072562 9.13 GC F2 ALB
3 Dsl1/NZR complex GO:0070939 8.62 RINT1 NBAS

Biological processes related to Acute Liver Failure according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of reactive oxygen species metabolic process GO:2000379 9.16 TSPO F2
2 anion transport GO:0006820 8.96 TSPO SLC17A5
3 transport GO:0006810 8.62 GC ALB

Sources for Acute Liver Failure

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....